1. Stone K. Renewal of the Prescription Drug User Fee Act (2013). http://pharma.about.com/od/FDA/a/2012-Renewal-Of-The-Prescription-Drug-User-Fee-Act-Pdufa.htm. Accessed November 10, 2014.
2. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance—lack of vigilance, lack of trust. JAMA. 2004; 292:2647.
3. Peart K. In drug-approval race, U.S. FDA ahead of Canada, Europe. Yale News. May 16, 2012. http://news.yale.edu/2012/05/16/drug-approval-race-us-fda-ahead-canada-europe. Accessed November 10, 2014.
4. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002; 287:2215–2218.
5. US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) statistics. 2012. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070434.htm. Accessed July 5, 2013.